Nasal inhalant category review by Medi-Cal coming to a close in April.
Executive Summary
MEDI-CAL NASAL INHALANT THERAPEUTIC CATEGORY REVIEW TO BE COMPLETED by the end of April, the California Medicaid agency reports. The agency's review of nasal inhalant therapies must be completed within 150 days, according to state law. Previous category reviews have considered ophthalmic agents, antidepressants, beta-blockers, antilipidemics, ulcer drugs, nonsteroidal anti-inflammatory drugs, ACE inhibitors and dermatologic anti-inflammatory drugs ("The Pink Sheet" Feb. 26, 1996, T&G-8).